surmount-osa trial tirzepatide results and Potential Role of in Treating Obesity-Related Obstructive Sleep Apnea — @atulmalhotra13 and @ljaronne presented Friday at #ADASciSessions. Read a recap in ADA Meeting News: https://t.co/Dg0qxKO7Pp Obstructive Sleep Apnea: An Evolving

Third Month: Stabilization and Consistency By the third month, it is very important to stay on track

The maximum approved dose is 15 mg once weekly

Concomitant use with other GLP-1 receptor agonists or incretin-based therapies is not recommended, as this combination has not been studied

So frustrating

Key takeaways Changes to menstrual cycles are not listed as specific side effects in the prescribing information for tirzepatide

Product Specifications Detailed Mechanism of Action When researchers buy tirzepatide and administer it in preclinical models, the molecule engages GIP receptors (GIPR) and GLP-1 receptors (GLP-1R) simultaneously